Back to Search Start Over

Targeting Kaposi's sarcoma associated herpesvirus encoded protease (ORF17) by a lysophosphatidic acid molecule for treating KSHV associated diseases.

Authors :
Rafeeq MM
Habib AH
Nahhas AF
Binothman N
Aljadani M
Almulhim J
Sain ZM
Alam MZ
Alturki NA
Alam Q
Manish M
Singh RK
Source :
Frontiers in cell and developmental biology [Front Cell Dev Biol] 2023 Jan 17; Vol. 11, pp. 1060156. Date of Electronic Publication: 2023 Jan 17 (Print Publication: 2023).
Publication Year :
2023

Abstract

Kaposi's sarcoma associated herpesvirus (KSHV) is causative agent of Kaposi's sarcoma, Multicentric Castleman Disease and Pleural effusion lymphoma. KSHV-encoded ORF17 encodes a protease which cleaves -Ala-Ala-, -Ala-Ser- or -Ala-Thr-bonds. The protease plays an important role in assembly and maturation of new infective virions. In the present study, we investigated expression pattern of KSHV-encoded protease during physiologically allowed as well as chemically induced reactivation condition. The results showed a direct and proportionate relationship between ORF17 expression with reactivation time. We employed virtual screening on a large database of natural products to identify an inhibitor of ORF17 for its plausible targeting and restricting Kaposi's sarcoma associated herpesvirus assembly/maturation. A library of 307,814 compounds of biological origin (A total 481,799 structures) has been used as a screen library. 1-oleoyl-2-hydroxy-sn-glycero-3-phospho-(1'-myo-inositol) was highly effective against ORF17 in in-vitro experiments. The screened compound was tested for the cytotoxic effect and potential for inhibiting Kaposi's sarcoma associated herpesvirus production upon induced reactivation by hypoxia, TPA and butyric acid. Treatment of reactivated KSHV-positive cells with 1-oleoyl-2-hydroxy-sn-glycero-3-phospho-(1'-myo-inositol) resulted in significant reduction in the production of Kaposi's sarcoma associated herpesvirus. The study identified a lysophosphatidic acid molecule for alternate strategy to inhibit KSHV-encoded protease and target Kaposi's sarcoma associated herpesvirus associated malignancies.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Rafeeq, Habib, Nahhas, Binothman, Aljadani, Almulhim, Sain, Alam, Alturki, Alam, Manish and Singh.)

Details

Language :
English
ISSN :
2296-634X
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in cell and developmental biology
Publication Type :
Academic Journal
Accession number :
36733461
Full Text :
https://doi.org/10.3389/fcell.2023.1060156